1. As of noon trading, DaVita HealthCare Partners ( DVA) is up $0.84 (0.8%) to $113.27 on light volume Thus far, 203,284 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 793,800 shares. The stock has ranged in price between $111.85-$113.27 after having opened the day at $112.60 as compared to the previous trading day's close of $112.43.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $10.7 billion and is part of the health care sector. The company has a P/E ratio of 20.3, above the S&P 500 P/E ratio of 17.7. Shares are up 47.5% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, growth in earnings per share, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full DaVita HealthCare Partners Ratings Report now.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Mining and Resources Lead Europe's Benchmarks Lower

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Here's What's Boosting European Benchmarks

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space